Literature DB >> 12422313

Epidermal growth factor receptor expression and measurement in solid tumors.

David C Spaulding1, Betsy O Spaulding.   

Abstract

The efficacies of targeted therapies for cancer treatment are dependent on the expression of the targeted molecule in the tumors of the treated patient population. Immunohistochemistry is an attractive assay format for determining protein expression in biopsies of solid tumors, and is widely used in pathology laboratories. An optimized immunohistochemistry assay for the epidermal growth factor receptor (EGFR) has been developed for the detection of EGFR in colorectal, head and neck, and other tumors that express EGFR, and the assay is being used in colorectal cancer trials of IMC-C225 to select patients for treatment. The specificity of the assay and the detection technology used will be described, along with other assay methodologies and applications for EGFR testing. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12422313     DOI: 10.1053/sonc.2002.35647

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  16 in total

1.  Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model.

Authors:  C Hope Heath; Nicholas L Deep; Larissa Sweeny; Kurt R Zinn; Eben L Rosenthal
Journal:  Ann Surg Oncol       Date:  2012-06-06       Impact factor: 5.344

2.  Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.

Authors:  Cheryl D Cho; George A Fisher; Joanne Halsey; Branimir I Sikic
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

Review 3.  Current targeted therapies in the treatment of advanced colorectal cancer: a review.

Authors:  Andrew Moriarity; Jacintha O'Sullivan; John Kennedy; Brian Mehigan; Paul McCormick
Journal:  Ther Adv Med Oncol       Date:  2016-05-29       Impact factor: 8.168

4.  Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways.

Authors:  Lei Zhen; Desheng Fan; Xianghua Yi; Xinming Cao; Dong Chen; Liming Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

5.  EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis.

Authors:  Fanny Burel-Vandenbos; Maxime Benchetrit; Catherine Miquel; Denys Fontaine; Romane Auvergne; Christine Lebrun-Frenay; Nathalie Cardot-Leccia; Jean-François Michiels; Veronique Paquis-Flucklinger; Thierry Virolle
Journal:  J Neurooncol       Date:  2010-07-24       Impact factor: 4.130

6.  Current status of pharmacological treatment of colorectal cancer.

Authors:  Reyhan Akhtar; Shammy Chandel; Pooja Sarotra; Bikash Medhi
Journal:  World J Gastrointest Oncol       Date:  2014-06-15

7.  A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.

Authors:  Rafal Wierzbicki; Derek J Jonker; Malcolm J Moore; Scott R Berry; Patrick J Loehrer; Hagop Youssoufian; Eric K Rowinsky
Journal:  Invest New Drugs       Date:  2009-10-15       Impact factor: 3.850

8.  Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.

Authors:  Giuseppe Giaccone; Renee B Iacona; Abderrahim Fandi; Mette Janas; Judith S Ochs; Roy S Herbst; David H Johnson
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-12       Impact factor: 4.553

Review 9.  Systemic treatment of colorectal cancer.

Authors:  Brian M Wolpin; Robert J Mayer
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

10.  Stereomicroscopic fluorescence imaging of head and neck cancer xenografts targeting CD147.

Authors:  J Robert Newman; John P Gleysteen; Christopher F Barañano; Jennifer R Bremser; Wenyue Zhang; Kurt R Zinn; Eben L Rosenthal
Journal:  Cancer Biol Ther       Date:  2008-04-14       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.